Connecticut Children's’ Post

RSV (Respiratory Syncytial Virus) affects not just individuals, but entire families. Check out this insightful article from Voices for Vaccines to learn more about how RSV impacts family dynamics and the importance of awareness and prevention. 🔗 [Link to the article]: How RSV Affects the Whole Family #RSVawareness #HealthcareEducation #FamilyHealth #VoicesForVaccines https://lnkd.in/evMxGGNG

This week is #RSVawareness week . Respiratory syncytial virus (RSV) is the leading cause of respiratory infection and hospitalisation in children . This is a particularly bad virus because it causes severe disease when our babies are really young ( less than 6months). Many of these babies end up in intensive care unit and require additional invasive oxygen support . Many will die unfortunately mostly in low middle income countries. After >50 years of research we have two passive immunization strategies to prevent RSV severe disease in babies . Let us all join in advocating for equitable access to these effective immunoprophylaixs for all babies , particularly those in #LMIC where the burden it highest . #vaccineequity #LMIC #RSV #ChildrenFirstAndForemost

#RSV #children #hospitalization #monoclonal #antibody #effectiveness In this multisite analysis of 699 infants hospitalized with ARI during their first RSV season, receipt of nirsevimab was 90% effective against RSV-associated hospitalization at a median of 45 days from receipt of nirsevimab to ARI symptom onset. This early effectiveness estimate supports existing recommen- dations for the prevention of severe RSV disease in infants in their first RSV season. The strengths of this first estimate of U.S. post-introduction nirsevimab effectiveness include enrollment of infants using a standardized ARI definition, systematic RSV testing, and receipt of nirsevimab verification with state immunization information systems or medical records for all infants. However, it is important to note that nirsevimab effectiveness during a full RSV season is expected to be lower than the estimate reported here, because antibody levels from passive immunization wane over time. In this analysis, the median interval from receipt of nirsevimab was 45 days, whereas the median duration of the U.S. RSV season before the COVID-19 pandemic was 189 days (8). In clinical trials, nirsevimab remained highly efficacious against RSV-associated lower respiratory tract infection in infants through 150 days after receipt of nirsevimab, consistent with an extended half-life of 63–73 days (9). Estimating effectiveness under real-world conditions for the full duration of an RSV season and in children aged 8–19 months at high risk for severe RSV disease who are recommended to receive nirsevimab before their second RSV season remains important. Thus, CDC will continue to moni- tor nirsevimab effectiveness.

The maternal RSV vaccine can prevent life-threatening illness in infants after birth. A health care professional’s recommendation plays a critical role in a patient’s decision to vaccinate. Learn more about recommending the RSV vaccine: https://bit.ly/3TG2uGv #SaferTogether #RSVAndMe

Flu Vaccine Numbers Fall: Are You Protected? 💉 As flu season approaches, it’s time to think about protecting yourself and those you care for. Last year, flu claimed the lives of thousands, and with the risk of a “tripledemic” of flu, COVID, and RSV, it’s more important than ever to stay protected. If you or the person you care for are eligible, you’ll be able to book a free vaccine from this month onwards. For more details on how to book a free vaccine this winter, visit the link in the article below 👇🏽 #FluVaccine #Caregivers #StayProtected #WeTalkCare #WinterWellness #FluSeason #BookNow #TripledemicProtection https://lnkd.in/eafAFqnb

Learn about the RSV vaccine and how it can protect seniors from respiratory syncytial virus. In this video, we'll cover the benefits, risks, and what to expect from the vaccine." Respiratory syncytial virus (RSV) can be a serious threat to seniors' health. But there's hope! The RSV vaccine is a powerful tool in preventing severe illness and hospitalization. In this video, we'll delve into the world of RSV and explore the vaccine's benefits, potential side effects, and who's most at risk. Watch now and take the first step in protecting yourself or your loved ones from RSV. https://lnkd.in/gD9nsD2u

Respiratory Syncytial Virus or RSV is a common cause of coughs and colds. RSV infections usually get better by themselves but can sometimes cause serious lung infections (pneumonia) which can be harmful for babies and older adults. That’s why the Isle of Man is offering the RSV vaccination to those most at risk. If you’re aged 75 – 79 years or are at least 28 weeks’ pregnant, you will be eligible and can find out more about the programme here https://lnkd.in/eE2Xei84

Today’s Ask the Experts question and answer is presented by ImmunizeOrg’s president and CEO, Dr. Kelly L. Moore. Established more than 25 years ago, our popular Ask the Experts feature offers answers to more than a thousand questions about vaccines and their administration. We regularly add new questions and answers to this feature, and review and revise all information to reflect current ACIP recommendations.       Find today’s video here: https://lnkd.in/eCgJcad6    To find the full set of ImmunizeOrg's Ask the Experts RSV Vaccine Q&As, visit: https://lnkd.in/e29KatW4    #ImmunizeOrg #vaccinessavelives #savelivesimmunize #vaccination #vaccineswork 

Respiratory Syncytial Virus or RSV is a common cause of coughs and colds. RSV infections usually get better by themselves but can sometimes cause serious lung infections (pneumonia) which can be harmful for babies and older adults. That’s why the Isle of Man is offering the RSV vaccination to those most at risk. If you’re aged 75 – 79 years or are at least 28 weeks’ pregnant, you will be eligible and can find out more about the programme here https://lnkd.in/eE2Xei84

As we approach RSV season, it's crucial to understand who's at risk and how to protect ourselves. RSV (Respiratory Syncytial Virus) can affect anyone, but certain groups are more vulnerable: 1. Infants and young children, especially premature babies 2. Adults between 60-74 with any underlying risks 3. Everyone over the age of 75 4. People with weakened immune systems 5. Those with chronic heart or lung conditions To protect yourself and loved ones: • Practice good hygiene (frequent handwashing) • Avoid close contact with sick individuals • Keep surfaces clean and disinfected • Consider RSV vaccination for eligible high-risk individuals If you or a loved one fall into a high-risk category, consult your healthcare provider about preventive measures and potential vaccination options. Stay informed, stay safe! #RSVAwareness #PublicHealth #PreventiveCare